A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML

Authors:

Abstract
Genomic profiling has allowed major advances in unraveling the complex molecular signature of acute myeloid leukemia (AML) and has informed us of the prognosis and survival of AML patients [1, 2]. ...
Funding Information
  • NIH (TL1 TR001858)
  • National Center for Advancing Translational Sciences

This publication has 18 references indexed in Scilit: